Core Points - Apollomics Inc. announced changes to its board of directors, with Mr. Po-Jen Hsueh resigning and Dr. Ya-Chi (Claudia) Huang appointed to fill the vacancy [1][2] - The current board now consists of seven members, including five independent directors [2] - Dr. Huang has extensive experience in biotechnology investment and corporate governance, previously serving in significant roles in the biopharmaceutical industry [3][4][5] Board Changes - Mr. Po-Jen Hsueh resigned from the board on November 16, 2025, with no disagreements reported [1] - Dr. Ya-Chi (Claudia) Huang was appointed to the board and will also serve on the Audit Committee and Nominating and Corporate Governance Committee [2] - The board now includes Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Dr. Huang [2] New Director's Background - Dr. Huang is currently the Assistant Vice President at Maxpro Ventures, leading investment activities and managing post-investment operations [4] - Previously, she was an Investment Manager at Diamond Biofund, where she oversaw multiple investments and contributed to the fund's IPO in 2023 [5] - Dr. Huang has a strong scientific background, with research published in notable journals and awards for her doctoral work [6] Company Overview - Apollomics Inc. focuses on developing oncology therapies, with its lead program being vebreltinib (APL-101), a selective c-Met inhibitor for non-small cell lung cancer [7]
Apollomics Announces Changes to its Board of Directors and Composition of Committees